Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: Result from a crossover study

Clinica Chimica Acta

Volumn 412, Issue 11-12, 2011, Pages 1068-1075

  Kawashiri, Masa aki ^a,b   Kobayashi, Junji ^a   Nohara, Atsushi ^a   Noguchi, Tohru ^a   Tada, Hayato ^a   Nakanishi, Chiaki ^a   Inazu, Akihiro ^a   Mabuchi, Hiroshi ^a   Yamagishi, Masakazu ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b KKR Hokuriku Hospital   (Japan)

Author keywords

Apolipoprotein E; Atorvastatin; Bezafibrate; Lipoprotein subclass; Remnant lipoprotein; Type III hyperlipoproteinemia

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; ATORVASTATIN; BEZAFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPERLIPOPROTEINEMIA TYPE 3; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MALE; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL;

AGED; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; BEZAFIBRATE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERLIPOPROTEINEMIA TYPE III; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS; MALE; MIDDLE AGED; PHENOTYPE; PYRROLES;

EID: 79955016643     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2011.02.026     Document Type: Article

References (28)

1. Rall S.C., Mahley R.W. Type III hyperlipoproteinemia (Dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism (15th Dec 2010). http://www.ommbid.com/OMMBID/the_online_metabolic_and_molecular_bases_of_inherited_disease/b/abstract/part12/ch119.
2. Kawashiri M.A., Higashikata T., Takata M., et al. Type III hyperlipoproteinemia exaggerated by Sheehan's syndrome with advanced systemic atherosclerosis: a 28-year clinical course. Circ J 2005, 69:746-751.
3. Mahley R.W., Huang Y., Rall S.C. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res 1999, 40:1933-1949.
4. Smelt A.H., de Beer F. Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects. Semin Vasc Med 2004, 4:249-257.
5. Mahley R.W., Ji Z.S. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 1999, 40:1-16.
6. Marx N., Duez H., Fruchart J.C., Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004, 94:1168-1178.
7. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report Circulation. 2002;106:3143-3421.
8. Kovanen P.T., Bilheimer D.W., Goldstein J.L., et al. Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog. Proc Natl Acad Sci USA 1981, 78:1194-1198.
9. East C.A., Grundy S.M., Bilheimer D.W. Preliminary report: treatment of type 3 hyperlipoproteinemia with mevinolin. Metabolism 1986, 35:97-98.
10. Vega G.L., East C., Grundy S.M. Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B. Atherosclerosis 1988, 70:131-143.
11. Ishigami M., Yamashita S., Sakai N., et al. Atorvastatin markedly improves type III hyperlipoproteinemia in association with reduction of both exogenous and endogenous apolipoprotein B-containing lipoproteins. Atherosclerosis 2003, 168:359-366.
12. van Dam M., Zwart M., de Beer F., et al. Long-term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia. Heart 2002, 88:234-238.
13. Usui S., Hara Y., Hosaki S., Okazaki M. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lipid Res 2002, 43:805-814.
14. Todo Y., Kobayashi J., Higashikata T., et al. Detailed analysis of serum lipids and lipoproteins from Japanese type III hyperlipoproteinemia with apolipoprotein E2/2 phenotype. Clin Chim Acta 2004, 348:35-40.
15. Kawashiri M.A., Nohara A., Tada H., et al. Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study. Clin Pharmacol Ther 2008, 83:731-739.
16. Huang Y.C., Kao J.T., Tsai K.S. Evaluation of two homogeneous methods for measuring high-density lipoprotein cholesterol. Clin Chem 1997, 43:1048-1055.
17. Usui S., Kakuuchi H., Okamoto M., et al. Differential reactivity of two homogeneous LDL-cholesterol methods to LDL and VLDL subfractions, as demonstrated by ultracentrifugation and HPLC. Clin Chem 2002, 48:1946-1954.
18. Nakajima K., Saito T., Tamura A., et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apoB-100 and anti apoA-I immunoaffinity mixed gel. Clin Chim Acta 1993, 223:53-71.
19. Civeira F., Cenarro A., Ferrand J., et al. Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia. Am Heart J 1999, 138:156-162.
20. Abourbih S., Filion K.B., Joseph L., et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systemic review. Am J Med 2009, 122:962.e1-962.e8.
21. Ayaori M., Momiyama Y., Fayad Z.A., et al. Effect of bezafibrate therapy on atherosclerotic aortic plaques detected by MRI in dyslipidemic patients with hypertriglyceridemia. Atherosclerosis 2008, 196:425-433.
22. Akanji A.O., Suresh C.G., Fatania H.R., et al. Associations of apolipoprotein E polymorphism with low-density lipoprotein size and subfraction profiles in Arab patients with coronary heart disease. Metabolism 2007, 56:484-490.
23. Clark R.W., Ruggeri R.B., Cunningham D., Bamberger M.J. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res 2006, 47:537-552.
24. Miwa K., Inazu A., Kawashiri M., et al. Cholesterol efflux from J774 macrophages and Fu5AH hepatoma cells to serum is preserved in CETP-deficient patients. Clin Chim Acta 2009, 402:19-24.
25. East C.A., Grundy S., Bilheimer D.W. Preliminary report: treatment of type 3 hyperlipoproteinemia with mevinolin. Metabolism 1986, 35:97-98.
26. Vega G.L., East C., Grundy S. Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B. Atherosclerosis 1988, 70:131-143.
27. Stuyt P.M., Mol M.J., Stalenhoef A.F., et al. Simvastatin in the effective reduction of plasma lipoprotein levels in familial dysbetalipoproteinemia (type III hyperlipoproteinemia). Am J Med 1990, 88:42N-45N.
28. Stuyt P.M., Mol M.J., Stalenhoef A.F. Long-term effects of simvastatin in familial dysbetalipoproteinemia. J Intern Med 1991, 230:151-155.